乳腺癌中CCR5和c-Met的表达及意义

目的探讨乳腺癌组织中CCR5和c-Met的表达及其意义。方法采用免疫组化SP法检测45例乳腺癌中CCR5和c-Met的表达。结果乳腺癌组织CCR5阳性率55.6%(25/45),正常乳腺组织中CCR5表达率8.9%(4/45),两种组织阳性表达率差异显著(P<0.01),c-Met的阳性表达率为51%(23/45),正常乳腺组织中c-Met表达率6.6%(3/45),两种组织阳性表达率差异显著(P<0.01)。在伴有淋巴结转移的乳腺癌中c-Met和CCR5的共同阳性率44.4%(20/45),无淋巴结转移的乳腺癌中阳性表达率为22.2%(10/45)。CCR5和c-Met的表达和乳腺癌的淋巴结转移成正相关。结论 CCR5和c-Met与提示乳腺癌的转移预后因素有关,可作为预测乳腺癌转移的参考指标之一。

Expression of CCR5 and c-Met in Breast Cancer and Its Significance

Objective To study the significance of CCR5 and c-Met expression in breast cancer. Methods The expression of CCR5 and c-Met in 45 eases of breast cancer was analyzed by using immunohistochemisty. Results CCR5 was expressed in 55.6% of cancerous breast tissue （25/45）, whereas it was only expressed in 8.9% of normal breast tissue （4/45）. Significant difference was noted between the expression levels （P〈0.01）. e-Met was expressed in 51% of cancerous breast tissue （23/45）, but only 6.6% （3/45） of normal tissue. The observed difference in expression level of c-Met was also statistically significant （P〈0.01）. On the other hand, 44.4% （20/45） of breast cancer patients with lymph node metastasis showed co-expression of both c-Met and CCR5, compared to 22.2% （10/45） in the normal breast tissue. Our findings demonstrate significant associations between the expression of c-Met, CCR5 and lymph node metastasis in breast cancer patients. Conclusion CCR5 and c-Met expression was associated with poor prognosis of breast cancer patients, which could be predict the prognosis of breast cancer.